July 08, 2024
2 min watch
On this video, Alexander Chehrazi-Raffle, MD, discusses the outcomes of a examine into the usage of JNJ-6520 in prostate most cancers, introduced at ASCO Annual Assembly.
Chehrazi-Raffle, a medical oncologist on the Metropolis of Hope Duarte Most cancers Heart, examined outcomes that appeared on the efforts of JNJ-6420 to bind human kallikrein (hK) 2 in metastatic castration-resistant prostate most cancers.
“It was the primary reported remedy that binds to hK 2, which is a brand new goal in prostate most cancers. And moreover, it is one of many first research to report outcomes utilizing actinium-225, which is a extremely energetic alpha omitting radioligand that holds quite a lot of promise in prostate most cancers,” Chehrazi-Raffle stated.
